Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions.
The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015.
Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 24 | -0.86 Increased by +43.79% | -0.87 Increased by +1.15% |
| May 15, 24 | -0.82 Increased by +39.26% | -1.07 Increased by +23.36% |
| Mar 28, 24 | -1.13 Increased by +16.30% | -0.77 Decreased by -46.75% |
| Nov 14, 23 | -0.95 Increased by +35.37% | -1.21 Increased by +21.49% |
| Aug 14, 23 | -1.53 Increased by +12.07% | -1.14 Decreased by -34.21% |
| May 15, 23 | -1.35 Increased by +26.23% | -1.33 Decreased by -1.50% |
| Mar 28, 23 | -1.35 Increased by +24.58% | -1.52 Increased by +11.18% |
| Nov 9, 22 | -1.47 Decreased by -13.08% | -1.77 Increased by +16.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -43.95 M Increased by +12.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -45.12 M Increased by +43.74% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -43.04 M Increased by +39.19% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -59.52 M Increased by +15.52% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -50.01 M Increased by +35.09% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -80.19 M Increased by +11.52% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -70.78 M Increased by +26.05% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -70.45 M Increased by +24.38% | Decreased by N/A% Decreased by N/A% |